3//SEC Filing
Vivo Capital Fund IX, L.P. 3
Accession 0001140361-21-036647
CIK 0001865494other
Filed
Nov 3, 8:00 PM ET
Accepted
Nov 4, 9:33 PM ET
Size
6.4 KB
Accession
0001140361-21-036647
Insider Transaction Report
Form 3
IO Biotech, Inc.IOBT
Vivo Capital Fund IX, L.P.
10% Owner
Holdings
Series C Preferred Stock
→ Common Stock (2,365,545 underlying)
Vivo Capital IX, LLC
10% Owner
Holdings
Series C Preferred Stock
→ Common Stock (2,365,545 underlying)
Footnotes (2)
- [F1]Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series C Preferred Stock beneficially owned by the reporting person will automatically convert, for no additional consideration, into the number of shares of Common Stock reported in Column 3. These shares of Series C Preferred Stock have no expiration date.
- [F2]The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.
Documents
Issuer
IO Biotech, Inc.
CIK 0001865494
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001750117
Filing Metadata
- Form type
- 3
- Filed
- Nov 3, 8:00 PM ET
- Accepted
- Nov 4, 9:33 PM ET
- Size
- 6.4 KB